Bristol-Myers Squibb Company (BMY)

59.86
0.60 1.01
NYSE : Health Care
Prev Close 59.26
Open 59.51
Day Low/High 59.30 / 60.04
52 Wk Low/High 51.82 / 77.12
Volume 10.58M
Avg Volume 9.08M
Exchange NYSE
Shares Outstanding 1.67B
Market Cap 99.07B
EPS 0.90
P/E Ratio 21.25
Div & Yield 1.52 (2.60%)

Latest News

Initiating a Position in a Biotech Name

Don't be surprised; we view Bristol-Myers as "down, not out."

Bristol-Myers Squibb Stock Will Bounce Back -- Here's How You Can Profit

Bristol-Myers Squibb Stock Will Bounce Back -- Here's How You Can Profit

BMY dropped after the bad news about a recent failed clinical trial of a new drug. But now the signs are there for a bullish reversal.

Pfizer Confirms $14 Billion Takeover of Cancer Drugmaker Medivation

Pfizer Confirms $14 Billion Takeover of Cancer Drugmaker Medivation

Acquiring Medivation will strengthen Pfizer's oncology franchise, which has lost ground in recent years to some Big Pharma competitors.

Sporting Goods Leveling Field, Which Stocks Say Interest Rates Are Rising: Jim Cramer's Best Blogs

Sporting Goods Leveling Field, Which Stocks Say Interest Rates Are Rising: Jim Cramer's Best Blogs

Jim Cramer ponders how the playing field is being leveled and how three stocks indicate a change in interest rates.

This Could Be a Bottom for Bristol-Myers

This Could Be a Bottom for Bristol-Myers

I do think we could rebound back into the $61-$62 range.

Jim Cramer -- Will Interest Rates Rise? Check These 3 Stocks

Jim Cramer -- Will Interest Rates Rise? Check These 3 Stocks

Johnson & Johnson, American Electric Power and Federal Realty say rates are going higher.

Cramer: 3 Stocks Say Interest Rates Are Going Higher

Cramer: 3 Stocks Say Interest Rates Are Going Higher

Be aware that Johnson & Johnson, American Electric Power and Federal Realty don't roll over idly.

Bristol-Myers Squibb (BMY) Stock Falls, Bernstein: Failed Trial Impact to Persist

Bristol-Myers Squibb (BMY) Stock Falls, Bernstein: Failed Trial Impact to Persist

Bernstein analysts say the impact of Bristol-Myers Squibb's (BMY) failed cancer drug trial will be "greater than many investors expect."

Realities of Retail; Remembrance of Probes Past: Jim Cramer’s Best Blogs

Realities of Retail; Remembrance of Probes Past: Jim Cramer’s Best Blogs

Jim Cramer ponders how retail is faring, and how the Valeant probe harkens back to a prior time.

Will Bristol-Myers (BMY) Stock Be Hurt by Downgrade?

Will Bristol-Myers (BMY) Stock Be Hurt by Downgrade?

Bristol-Myers' (BMY) stock rating was cut to 'hold' from 'buy' at Berenberg on Thursday.

Jim Cramer Says Government Probe Not a Reason to Sell Valeant, But There are Other Reasons

Jim Cramer Says Government Probe Not a Reason to Sell Valeant, But There are Other Reasons

The government's investigation into Valeant sn't a reason to sell the stock, but there are plenty of other reasons not to own it, according to Jim Cramer.

Jim Cramer -- There Are Plenty of Reasons to Sell Valeant

Jim Cramer -- There Are Plenty of Reasons to Sell Valeant

Don't sell the stock just because of the reported federal investigation, Cramer says.

Cramer: Valeant Probe Is a Reminder of the Bristol-Myers Scandal

Cramer: Valeant Probe Is a Reminder of the Bristol-Myers Scandal

Go ahead and sell Valeant on the news, if you want. But history has a different lesson.

4 Stocks to Avoid Amid the Mad 'Search for Yield'

4 Stocks to Avoid Amid the Mad 'Search for Yield'

There's a price to pay for low expectations.

Don't Write Off Bristol-Myers After Opdivo Setback

Don't Write Off Bristol-Myers After Opdivo Setback

BMY is unlikely to stay in the low $60s for long.

Bristol Myers Offers Strong Risk/Reward Trade Now

Bristol Myers Offers Strong Risk/Reward Trade Now

Wise investors should not follow analysts who have downgraded Bristol Myers Squibb, but should instead purchase the stock on sale.

What Hath Good Breadth Wrought?

This isn't doing a great deal for the market.

Stocks Retreat From Records as Health Care Slumps

Stocks Retreat From Records as Health Care Slumps

Stocks retreat from record highs on Monday as a selloff in health care overshadows a rally in energy.

The Ironic Chess Game of Bristol-Myers

The Ironic Chess Game of Bristol-Myers

The failed trial is among the biggest single blows by a major pharma player.

Stocks Fall as Health Care Selloff Counters Energy Rally

Stocks Fall as Health Care Selloff Counters Energy Rally

Stocks pull slightly lower on Monday as a selloff in health care squares off against a rally in energy.

Bullish and Bearish Reversals for the Week

Bullish and Bearish Reversals for the Week

Energy, financial and technology stocks dominate names showing potential for higher prices.

Trending Tickers: CHK, MUR, MRO, BMY

Trending Tickers: CHK, MUR, MRO, BMY

Rising crude prices help buoy a host of oil companies Monday.

Jim Cramer -- I'm Worried About Not Being Worried

Jim Cramer -- I'm Worried About Not Being Worried

We should be hearing more bad news from the banks but we're not. Cramer wants to know why.

Midday Report: Bristol-Myers Drags Health Care Lower; U.S. Stocks Slip

Midday Report: Bristol-Myers Drags Health Care Lower; U.S. Stocks Slip

U.S. stocks pulled lower as a selloff in health care soured the jobs-inspired rally that pushed benchmark indices to record highs last week.

Bristol-Myers Downgraded, Credit Suisse Lowers Price Target

Bristol-Myers Downgraded, Credit Suisse Lowers Price Target

Credit Suisse downgraded Bristol-Myers Squibb to NEUTRAL from OUTPERFORM and lowered its price target to $63 from $86 following the latest announcement on Opdivo.

Jim Cramer: Allergan & Bristol-Myers Are Misunderstood

Jim Cramer: Allergan & Bristol-Myers Are Misunderstood

Jim Cramer says the markets don't understand Bristol-Myers Squibb and Allergan.

Health Care Drags Stocks Away From Records

Health Care Drags Stocks Away From Records

Stocks pull lower on Monday morning as a selloff in health care sours the jobs-inspired rally that pushed benchmark indices to record highs last week.

How Bad Does Bristol-Myers Squibb Look After Friday?

How Bad Does Bristol-Myers Squibb Look After Friday?

A lot of price damage has been inflicted on this stock.